PAM
BMRN icon

Paradigm Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Paradigm Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,200
Closed -$711K – 808
2015
Q2 		$711K Hold
5,200
– – 0.08% 254
2015
Q1 		$648K Buy
+5,200
New +$551K 0.07% 266

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Paradigm Asset Management's BMRN Position: Q3 2015 in Review

Paradigm Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 5,200 shares — an estimated $711K sold.

Paradigm Asset Management first reported a position in BMRN in Q1 2015 and held it in 2 quarters. The position peaked at $711K in Q2 2015. 393 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

  • Paradigm Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Paradigm Asset Management sold 5,200 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $711K.
  • Paradigm Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Paradigm Asset Management's BioMarin Pharmaceuticals position peaked at $711K in Q2 2015.
  • 393 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Paradigm Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.